ERBB2 and breast carcinoma: Furthermore, HER2-negative breast cancers were significantly more prevalent among BRCA1 (98.2% vs 77.7%, p < 0.001) and BRCA2 (95.0% vs 77.7%, p = 0.001) PV carriers than non-PV carriers (Table 3).